CervoMed Inc.

CRVO

$2.57

+1.18%

2026-09-04 11:31:48 EDT+$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing ...

Price Action of CRVO

$2.57

+1.18%+$0.03

High—

Low—

52W High-76.1%

Rel. vol—

Interval

Range89m

Volume—SMA5SMA10

—

CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, focused on developing treatments for age-related neurologic disorders. The company's lead product candidate, neflamapimod, is an orally administered small molecule that crosses the blood-brain barrier and inhibits the enzyme p38 alpha. This mechanism has the potential to ...CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, focused on developing treatments for age-related neurologic disorders. The company's lead product candidate, neflamapimod, is an orally administered small molecule that crosses the blood-brain barrier and inhibits the enzyme p38 alpha. This mechanism has the potential to reverse synaptic dysfunction, improve neuronal health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis (ALS), and other indications. Founded in 2010 (originally as EIP Pharma, later merged with CervoMed in 2023), the company has been led by CEO and co-founder Dr. John Alam since its inception. As a clinical-stage company, CervoMed has not yet generated product revenue, and its financials reflect significant research and development expenses. The company employs about 15 people as of the latest data, with a focus on advancing its pipeline. CervoMed's total market capitalization is around $28 million as of the provided data, with a stock price of $3.07. The company's cash position and working capital are strong, but it continues to incur net losses as it progresses through clinical trials. Key financial metrics include a negative net profit margin, high R&D intensity, and a strong balance sheet with no debt. CervoMed's mission is to develop innovative therapies that address the underlying pathology of neurodegenerative diseases, offering hope to patients and their families. The company's dedication to scientific excellence and patient care underscores its long-term vision in the biotechnology industry.ExpandCollapse

Founded

2010

Employees

CEO

John J. Alam

Full Name

CervoMed Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-156.02%

Market Cap

$0.04B

Current Ratio

8.57

WACC

5.48%

ROIC

-132.18%

Contact Information

https://www.cervomed.com

617-744-4400

20 Park Plaza, Boston, MA 02116

Key Metrics of CRVO

Snapshot

Latest / TTM · 6 periods

Market Cap

$38.86M

ROCE

-135.7%

EV / EBITDA

-0.03x

+15.2% YoY

FCF Yield

-119.0%

-86.1% YoY

Cash Conversion Cycle

0.0d

Current Ratio

8.57

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of CRVO

Profitability trend

Latest / TTM · 6 periods

Gross Margin

100.0%

Net Margin

-9408.8%

P/E Ratio

-0.79x

n/a

Debt / Equity

0.00

n/a

Current Ratio

8.57

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of CRVO

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.49 · Revenue $50000.00 · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.45 · Revenue $83333.00 · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-2.15 · Revenue $133333.00 · 5 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.40 · Revenue $250000.00 · 1 analysts

Recent history

Aug 7, 2026
Q2 FY2026 · Results reported
EPS $-0.64 · Revenue $0.00
View filing
May 15, 2026
Q1 FY2026 · Results reported
EPS $-0.86 · Revenue $0.00
View filing
Mar 13, 2026
FY2025 · Annual results
EPS $-2.98 · Revenue $0.00
View filing
Sep 30, 2025
Q3 FY2025 · Results reported
EPS $-0.84 · Revenue $322569.00
Jun 30, 2025
Q2 FY2025 · Results reported
EPS $-0.70 · Revenue $0.00
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.56 · Revenue $0.00

Financial Statements of CRVO

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-27.0M	-65.5%	+17.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-23.4M	-41.9%	+13.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	—	—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	4.84x	-56.4%	+155.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$23.4M	-45.7%	+72.0%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-2.98 vs -2.97	-0.2%	-0.64 vs -0.49	-30.6%
Revenue Surprise	$0 vs $3.6M	-100.0%	$0 vs $50000	-100.0%

Insider Transactions of CRVO

Acquisitions (A)

Since Jun 8, 2026

Disposals (D)

Since Jun 8, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 11, 2026	BOGER JOSHUA S	director, 10 percent owner:	Common Stock	A	955,414	$3.14
Jun 11, 2026	BOGER JOSHUA S	director, 10 percent owner:	Series B Warrants	A	955,414	$3.32
Jun 11, 2026	BOGER JOSHUA S	director, 10 percent owner:	Series C Warrants	A	955,414	$3.14
Jun 8, 2026	ZAVRL FRANK	director	Stock Option (Right to Buy)	A	8,150	$2.91
Jun 8, 2026	Sabbagh Marwan	director	Stock Option (Right to Buy)	A	8,150	$2.91

Leadership Team of CRVO

8 executives

Name	Title	Compensation	Gender	Year Born	Status
John J. Alam	Co-Founder, Chief Executive Officer, President & Director	USD 952,940	—	1962	Active
William Robert Elder	Chief Financial Officer, General Counsel & Corporate Secretary	USD 643,664	Male	1983	Active
Kelly Blackburn	Executive Vice President of Clinical Development	USD 609,939	Female	1964	Active
Sylvie L. Gregoire	Co-Founder & Director	USD 40,000	—	1961	Active
Mark A. De Rosch	Executive Vice President of Regulatory, Government Affairs & Program Management	—	—	1964	Active
Marinus Verwijs	Executive Vice President of Technical Operations	—	—	1976	Active
Claudia Ordonez	Senior Vice President of Medical Science	—	—	1966	Active
Matthew Winton	Chief Commercial & Business Officer	—	—	1978	Active

Recent News of CRVO

GlobeNewsWire8/10/2026Neutral

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.

GlobeNewsWire8/5/2026Neutral

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

GlobeNewsWire8/4/2026Neutral

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

GlobeNewsWire7/14/2026Neutral

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

GlobeNewsWire7/9/2026Neutral

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference

Historical Employee Count of CRVO

Current

Change

+0.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	15	10-K	Mar 13, 2026	View
Dec 31, 2024	15	10-K	Mar 17, 2025	View
Dec 31, 2023	8	10-K	Mar 29, 2024	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

CervoMed Inc.